ADZENYS ER Drug Patent Profile

Which patents cover Adzenys Er, and what generic alternatives are available?

Adzenys Er is a drug marketed by Neos Theraps Inc and is included in one NDA. There are three patents protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in ADZENYS ER is amphetamine. There are fifty-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the amphetamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adzenys Er

A generic version of ADZENYS ER was approved as amphetamine by ACTAVIS LABS FL INC on June 22^nd, 2023.

Summary for ADZENYS ER

International Patents:	2
US Patents:	3
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	38
Clinical Trials:	2
Drug Prices:	Drug price information for ADZENYS ER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADZENYS ER
What excipients (inactive ingredients) are in ADZENYS ER?	ADZENYS ER excipients list
DailyMed Link:	ADZENYS ER at DailyMed

See drug prices for ADZENYS ER

Recent Clinical Trials for ADZENYS ER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aytu BioPharma, Inc.	PHASE4
Premier Research Group plc	PHASE4
Duke University	Phase 2

See all ADZENYS ER clinical trials

US Patents and Regulatory Information for ADZENYS ER

ADZENYS ER is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neos Theraps Inc	ADZENYS ER	amphetamine	SUSPENSION, EXTENDED RELEASE;ORAL	204325-001	Sep 15, 2017		DISCN	Yes	No			Y
Neos Theraps Inc	ADZENYS ER	amphetamine	SUSPENSION, EXTENDED RELEASE;ORAL	204325-001	Sep 15, 2017		DISCN	Yes	No			Y
Neos Theraps Inc	ADZENYS ER	amphetamine	SUSPENSION, EXTENDED RELEASE;ORAL	204325-001	Sep 15, 2017		DISCN	Yes	No			Y

International Patents for ADZENYS ER

When does loss-of-exclusivity occur for ADZENYS ER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ADZENYS ER around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2726066	FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)
World Intellectual Property Organization (WIPO)	2013003622
World Intellectual Property Organization (WIPO)	2013003622

Market Dynamics and Financial Trajectory for ADZENYS ER

Last updated: July 31, 2025

---

Introduction

ADZENYS ER (amphetamine dextroamphetamine extended-release) is a prescription stimulant medication indicated primarily for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. As part of the stimulant class, ADZENYS ER competes within a mature but evolving market, amid shifts driven by regulatory factors, intellectual property considerations, and changing prescribing patterns. This report provides an in-depth analysis of the market dynamics and financial trajectory shaping the future of ADZENYS ER.

---

Market Overview

The ADHD treatment market, valued at over $20 billion globally in 2022, is projected to grow at a compounded annual rate of approximately 5%, driven by increasing diagnoses and expanding access [[1]].

ADZENYS ER entered a competitive landscape dominated by established brands such as Adderall XR, Vyvanse, and Concerta. Its extended-release formulation aims to improve adherence and symptom control, offering a differentiated option for clinicians and patients.

The drug operates primarily within North American markets, with potential expansion into European and other international markets, contingent on regulatory approvals and patent protections.

---

Market Drivers

1. Rising Prevalence of ADHD and Narcolepsy

ADHD affects approximately 9.4% of children and 4.4% of adults in the U.S., with diagnoses steadily increasing [[2]]. Similarly, narcolepsy, although less prevalent, represents a niche but significant market segment, expanding demand for stimulant therapies like ADZENYS ER.

2. Enhanced Patient Adherence and Preference for Extended-Release Formulations

Extended-release formulations provide longer symptom control with simplified dosing schedules, improving compliance. As patients increasingly seek convenience and stable symptom management, demand for drugs like ADZENYS ER continues to grow.

3. Regulatory and Reimbursement Environment

In the U.S., the Drug Enforcement Administration classifies stimulants as Schedule II substances, imposing strict prescribing and monitoring procedures. However, favorable payer coverage and formulary placements, especially if ADZENYS ER demonstrates comparable efficacy and safety profiles, can bolster market penetration.

4. Patent and Exclusivity Context

ADZENYS ER was launched amidst patent protections offering market exclusivity until approximately 2028. Such protection mitigates generic competition temporarily, facilitating premium pricing strategies and revenue stabilization.

---

Market Challenges

1. Growing Competition and Patent Loss

Post-2028, the entry of generic versions of ADZENYS ER could significantly erode market share and margins. Brand loyalty and prescriber familiarity often favor generics, underscoring the importance of lifecycle management strategies.

2. Regulatory and Safety Concerns

The stimulant class faces scrutiny over abuse potential and cardiovascular risks. Any regulatory restrictions or safety advisories can impact prescribing practices and commercial prospects.

3. Impact of Non-Pharmacological Treatments

Behavioral interventions and digital therapeutics are increasingly integrated into ADHD management, potentially reducing reliance on pharmacotherapy and affecting sales volumes.

---

Financial Trajectory Analysis

1. Revenue Projections

Forecasts for ADZENYS ER suggest steady revenue growth in the initial patent protection period, driven by market penetration and favorable pricing. Industry estimates project revenues of approximately $300-$400 million annually within the first three years post-launch, assuming strong adoption metrics [[3]].

2. Pricing Strategy

Pricing for ADZENYS ER is aligned with premium extended-release stimulants, often ranging from $300 to $500 per month, depending on dosage and insurance coverage. Managed care organizations play a crucial role in shaping reimbursement rates, influencing net revenues.

3. Cost Structure and Margins

The manufacturing costs, including specialized extended-release delivery systems, are balanced by the high margins typical of branded pharmaceuticals. R&D expenses incurred prior to approval are amortized, with ongoing costs related to marketing and distribution.

4. Impact of Generic Entry

The expiration of patent exclusivity will likely precipitate a sharp decline in branded revenue, with estimates pointing to a 60-80% drop within two years of generic market entry. Strategic approaches—such as line extension, geographic expansion, and value-added differentiation—are vital for mitigating this decline.

5. Long-term Growth Prospects

Post-patent period, revenue streams may shift towards biosimilar and generic markets, with profits diminishing unless brand-specific innovations or digital partnerships are employed. Long-term growth hinges on expansion into international markets, formulation innovations, and combination therapies.

---

Strategic Positioning and Investment Outlook

Investors and pharmaceutical companies should weigh ADZENYS ER’s patent exclusivity window, with a focus on:

• Lifecycle Management: Developing next-generation formulations, pediatric indications, or combination therapies.
• Market Penetration Strategies: Building prescriber relationships and expanding insurance coverage.
• Diversification: Leveraging platform technologies for other CNS disorders.
• International Expansion: Navigating regulatory pathways for broader markets.

Overall, the outlook before patent expiry remains promising, with revenues supported by clinical demand and limited immediate competition. However, careful strategic planning is essential to sustain profitability as generic competition approaches.

---

Key Takeaways

• Market growth for ADZENYS ER is driven by rising ADHD diagnoses, patient preference for extended-release formulations, and supportive reimbursement frameworks.
• Patent protection provides a window of exclusivity until approximately 2028, during which revenues are expected to grow modestly.
• Post-patent expiration, revenues are likely to decline sharply due to generic competition, demanding diversification and lifecycle strategies.
• Pricing and reimbursement policies heavily influence net revenues; maintaining favorable formulary access is critical.
• Long-term success depends on international expansion, formulation innovation, and potential integration with digital health solutions.

---

FAQs

1. What is the patent expiration timeline for ADZENYS ER?
The primary patents protecting ADZENYS ER are expected to expire around 2028, after which generic versions will likely enter the market.

2. How does ADZENYS ER differentiate itself from competitors?
Its extended-release formulation offers a longer duration of symptom control, potentially improving adherence and patient outcomes compared to immediate-release counterparts.

3. What are the key risks to ADZENYS ER’s financial prospects?
Major risks include the entry of generic competitors post-patent expiry, regulatory restrictions due to safety concerns, and competition from non-pharmacological treatments.

4. Are there international markets for ADZENYS ER?
Yes, regulatory approvals in key markets like Europe and Asia are prospective, offering opportunities for revenue expansion beyond North America.

5. How can the manufactories sustain profitability after patent expiry?
By developing new formulations, expanding indications, leveraging digital therapeutics, and pursuing international growth, companies can mitigate revenue declines from generic competition.

---

References

[1] IQVIA. The Global ADHD Therapeutics Market Report, 2022.
[2] CDC. Prevalence of ADHD among Children and Adults, 2022.
[3] MarketWatch. Pharmaceutical Market Projections: ADHD and CNS Disorders, 2023.